Association of interferon gamma gene polymorphism and susceptibility to hepatitis C virus infection in Egyptian patients: A multicenter, family-based study

Mahmoud El-Bendary, Mustafa Neamatallah, Hatem Elalfy, Tarek Besheer, Maged El-Setouhy, Nihal Kasim, Noha T Abou El-Khier, Emily Kamel, Abdel-Aziz F Abdel-Aziz and Gamal Esmat

*Tropical Medicine and Hepatology Department, Mansoura Faculty of Medicine, #Medical Biochemistry Department, Mansoura Faculty of Medicine, †Biochemistry Department, Faculty of Science, ‡Medical Microbiology and Immunology Department, Faculty of Medicine, **Public Health and Preventive Medicine Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, ††Department of Community, Environmental and Occupational Medicine, Ain-Shams Faculty of Medicine, Ain-Shams University, Cairo, ‡‡Internal Medicine Department, Alazhar Faculty of Medicine, Assiut University, Assiut, †††Tropical Medicine and Hepatology Department, Cairo Faculty of Medicine, Cairo University, Giza, Egypt and §Substance Abuse Research Center (SARC), Jazan University, Jazan, Kingdom of Saudi Arabia

Key words
gene polymorphism, hepatitis C virus susceptibility, interferon gamma, intrafamilial, viral clearance.

Accepted for publication 3 October 2017.

Correspondence
Professor Mahmoud El-Bendary, Tropical Medicine and Hepatology Department, Mansoura Faculty of Medicine, Mansoura University, Elgomhorya street, Mansoura 35111, Egypt. Email: mmelbendary@gmail.com

Declaration of conflict of interest: None.

Financial support: This research was funded by Science & Technology Development Foundation (STDF), Project No. 1784 (TC/2/Health/2009/ hep-1.3).

Funding support: This research was funded by Science & Technology Development Foundation (STDF) Project No.1784 (TC/2/Health/2009/hep-1.3).

Abstract

Background and Aim: Polymorphisms in some genes may influence the persistence of hepatitis C virus (HCV) infection, clinical outcome, HCV replication, and liver damage. This study was conducted to investigate the role of the interferon gamma (IFN-γ) gene at (+874 T/A, −764 G/C, −179 C/A) single-nucleotide polymorphisms (SNPs) and its receptor (IFN-γR2) at (rs 2786067 A/C) SNP in the susceptibility of Egyptian families to HCV infection with high-resolution techniques.

Methods: In total, 517 Egyptian families, with 2246 subjects, were recruited to this study from the Upper and Lower Egypt governorates and were classified into three groups: 1034 patients with chronic hepatitis C virus, 108 subjects with spontaneous virus clearance (SVC), and 1104 subjects as a healthy control group. All subjects were genotyped for (+874 T/A, rs2430561, −764 G/C, rs2069707, −179 C/A, rs2069709, and rs 2786067, A/C) SNPs of the IFN-γ gene using the allelic discrimination real-time polymerase chain reaction technique and were confirmed using sequence-based typing.

Results: The carriage of T allele of (+874) IFN-γ is a risky allele and was significantly higher in chronic hepatitis C more than other two groups (odds ratio [OR]: 2.6646, P < 0.0002). On the other hand, the C allele of (−764, rs2069707) is a protective allele and was higher in SVC than the other two groups (OR: 0.2709, P < 0.0001). However, both (−179 C/A, rs2069709) and (rs 2786067, A/C) SNPs are not polymorphic enough to be studied in the Egyptian population.

Conclusions: HCV infection is associated with the T allele of (+874) rs2430561), while SVC of HCV is associated with the C allele of (−764, rs2069707) of the IFN-γ gene.

Introduction

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide.1 The prevalence of HCV infection is estimated to be about 3% in the world.2 It was reported that around 15% of the Egyptian population has chronic hepatitis C virus. Over 90% of the infections have been reported to be HCV genotype 4.3,4

The virus entry is associated with interferons (IFNs) release within the cell.5 IFNs, especially interferon gamma (IFN-γ), which is a secretory protein mainly produced by T and natural killer cells, counteract the viral replication either by direct inhibition or via activation of the immunoregulatory mechanisms responsible for the control of HCV infection.6

Previous sequence analysis revealed several polymorphisms within the IFN-γ gene.7,8 These polymorphisms are located in different sites along the IFN-γ gene, including (+874 T/A, −764 C/G, −179 G/T) loci.9−11 However, the (+874 T/A, rs2430561) single-nucleotide polymorphism (SNP) can influence IFN-γ expression.7 Expression of IFN-γ is genetically controlled, and the presence of alleles T and A at the +874 position from the translation start site is related to high and low IFN-γ expression, respectively, which in turn influences the activity of HCV.8,9,12

The SNP (rs2069707 C/G) of the IFN-γ gene is located in the proximal promoter region at position −764, next to the binding motif for HSF1.10 Some data support the hypothesis that the
SNP variant −764 G is an important genetic marker for treatment response and spontaneous recovery in HCV infection.13,14

Other studies demonstrated that IFN-γ SNPs appear to affect IFN-γ expression, such as rs2069709, which is a G to T transition at position −179 bp in the promoter region.11 Several studies on (−179 G/T, rs2069709) showed that SNP has been implicated in several autoimmune and chronic inflammatory conditions. However, none of them has been shown to be related to HCV infection.15

Impaired function of IFN-γ receptors might lead to increased production of IFN-γ, as seen in patients with complete IFN-γ receptor deficiencies.16,17 The identification of a cluster of IFN-γR2 variants, which are strongly associated with liver fibrosis progression in CHCV infection, underlines the role of IFN-γ in the development of liver fibrosis that may pave the way for new treatments.17

**Aim of the study**

This study was conducted to investigate the association of the IFN-γ gene, and its receptors, polymorphism with HCV infection outcomes (either susceptibility or clearance) in Egyptian families with high-resolution techniques.

**Subjects and methods**

**Study population.** This multicenter study was carried out in the Molecular Genetic Unit, Faculty of Medicine, Mansoura University between 2011 and 2016. We included Egyptian HCV patients and their families or close household contacts from different populations, including upper, middle, and lower Egypt. Each family was selected based on the following: at least one positive HCV patient as an index patient, one positive HCV household member and one negative HCV member with no history of any liver complications or disorders.

In total, 517 Egyptian families in this study were recruited from Dakahlia, Cairo, and Assuit governorates. Their families included 2246 subjects:1034 CHC cases (cases with positive antibody positive but HCV-RNA negative in two successive samples at least 6 months apart. The HCV-positive group in the antibody positive but HCV-RNA negative in two successive virus clearance (SVC) group cases, who demonstrated HCV group cases (cases with negative PCR HCV >6 months), 1104 control polymerase chain reaction [PCR] HCV >6 months), 1104 control samples from Dakahlia, Cairo, and Assuit governorates. Their families diversity between 2011 and 2016. We included Egyptian HCV patients and their families or close household contacts from different populations, including upper, middle, and lower Egypt. Each family was selected based on the following: at least one positive HCV patient as an index patient, one positive HCV household member and one negative HCV member with no history of any liver complications or disorders.

In total, 517 Egyptian families in this study were recruited from Dakahlia, Cairo, and Assuit governorates. Their families included 2246 subjects:1034 CHC cases (cases with positive antibody positive but HCV-RNA negative in two successive samples at least 6 months apart. The HCV-positive group in the antibody positive but HCV-RNA negative in two successive virus clearance (SVC) group cases, who demonstrated HCV group cases (cases with negative PCR HCV >6 months), 1104 control polymerase chain reaction [PCR] HCV >6 months), 1104 control samples from Dakahlia, Cairo, and Assuit governorates. Their families diversity between 2011 and 2016. We included Egyptian HCV patients and their families or close household contacts from different populations, including upper, middle, and lower Egypt. Each family was selected based on the following: at least one positive HCV patient as an index patient, one positive HCV household member and one negative HCV member with no history of any liver complications or disorders.

Exclusion criteria of index cases included: patients infected with HIV or HBV (HBV core antibodies), patients positive for anti-HCV antibodies, and no detectable HCV-RNA in the serum. Patients with autoimmune hepatitis, hepatocellular carcinoma (HCC), and metabolic liver diseases were also excluded. Healthy household controls were included in this study using the following inclusion criteria: individuals of both genders and age > 18 years; first- and second-degree consanguinity to the index case; living and sharing usual family activity with the index case; having no serological evidence of HCV, HBV, or HCC; and having no history of liver disease. Each participant was subjected to routine clinical and laboratory investigations by a clinician in addition to PCR HCV RNA analysis to confirm HCV infection, and genetic polymorphism of four snips of the IFN-γ gene (+874 T/A, rs2430561, −764 G/C, rs2069707, −179 C/A, rs2069709, and rs27860067, A/C) were performed for all subjects as well.

Written informed consent was obtained from each participant. The study was reviewed and approved by the institution’s human research committee.

**Laboratory methods**

**Genomic DNA extraction from peripheral blood.** Genomic DNA extraction from peripheral blood was performed for all subjects using a commercial Qiagen DNA isolation kit (QiAmp DNA Mini kit; Qiagen, Hilden's, Germany) following the manufacturer’s instructions. The DNA was assessed using a NanoDrop spectrophotometer (NanoDrop™2000/2000c spectrophotometer, Thermo Scientific, CA, USA) and 2% ethidium bromide-stained agarose gel to confirm their integrity.

**IFN-γ (+874 T/A, rs2430561) polymorphism.** Polymorphism of IFN-γ (+874 T/A, rs2430561) was genotyped using amplification-refractory mutation system (ARMS)-PCR and confirmed using sequence-based typing (SBT) (Table 1).

**Genotyping of IFN-γ (+874 T/A, rs2430561) polymorphism using ARMS-PCR technique.** The T and A polymorphism sequences were identified using a specific primer synthesized to cover a 24-bp region for each allele. The primers were designed using primer 3 plus (v 4.1; ABI Universal PCR Master Mix, Applied Biosystems, Foster City, CA, USA). ARMS-PCR was performed in a total volume of 20 μL primer containing 1 μL of generic primer (100 pmol/μL; 5’ TCAACAAACGGTTAATCTCCA 3’), 1 μL of specific A primer (100 pmol/μL, 5’ TTCTTACAAACA- CAAAATACATACT 3’), or 1 μL of specific T primer (100 pmol/μL, 5’ TTCTTACAAACAAAATCT 3’). In addition, internal control of the growth hormone gene (GH) primers was used with each sample as follows: 1 μL of forward (10 pmol/μL, 5’ GCCTTCCCACACATCTTCT 3’), 1 μL of reverse (10 pmol/μL, 5’ TACGGATTGTGTTGTTGTGC 3’), 4 μL of dNTP (2 mM), 2.4 μL of MgCl2 (25 mM), 3 μL of buffer (10×), 0.5 μL of the growth hormone gene (GH) primers was used with each sample as follows: 1 μL of forward (10 pmol/μL, 5’ GCCTTCCCACACATCTTCT 3’), 1 μL of reverse (10 pmol/μL, 5’ TACGGATTGTGTTGTTGTTGC 3’), 4 μL of dNTP (2 mM), 2.4 μL of MgCl2 (25 mM), 3 μL of buffer (10×), 0.5 μL of

**Table 1** SNPs selected within the IFN-γ gene and its receptor (IFN-γR2)

| Gene   | Cyogenetic region | Marker       | Position | Location | SNP (alleles) | Methods of PCR technique                                |
|--------|-------------------|--------------|----------|----------|--------------|--------------------------------------------------------|
| IFN-γ  | 12q15             | rs2069707    | −764     | Promoter | G/C          | TaqMan Allelic discrimination Real Time                |
|        |                   | rs2069709    | −179     | Promoter | C/A          | TaqMan Allelic discrimination Real Time                |
|        |                   | rs2430561    | +874     | Intron 1 | T/A          | ARMS and DNA sequencing                                 |
| IFN-γR2 | 21q22.11         | rs27860067   | —        | Exon 3   | A/C          | TaqMan Allelic discrimination Real Time                |
of Taq DNA polymerase (5 U/μL), 4.1 μL of sterile MilliQ H2O, and 2 μL of genomic DNA.

ARMS-PCR was performed in a thermal cycler 7500 real time PCR system (Applied Biosystems, Foster City, CA, USA) with the following cycles: initial denaturation, 95°C (10 min); 40 cycles of denaturation, 95°C (1 min); annealing, 47°C (30 s); and extension, 72°C (1 min), followed by final extension, 72°C (10 min) and 4°C (hold temperature). ARMS-PCR-amplified products were subjected to 2% agarose gel electrophoresis, stained with ethidium bromide, and visualized on an ultraviolet transilluminator.

**Typing of IFN-γ (+874 T/A, rs2430561) polymorphism using SBT technique.** The IFN-γ (+874 T/A, rs2430561) polymorphism gene was typed using the SBT technique. Amplification was first determined using the ARMS-PCR method. The PCR reaction was obtained using a thermal cycler (Applied Biosystems, 2720). A cycle sequence was performed for the purified PCR product in the forward direction by the reverse primer using Big Dye Terminator Cycle Sequencing Kits (version 3.0) according to manufacturer’s instructions. Sequenced products were then separated by capillary electrophoresis (Applied Biosystems 310 Genetic Analyzer). Sequences were analyzed with dedicated software.

**Genotyping of (rs2069707, rs2069709) SNP of IFN-γ gene and (rs 27860067) SNP of IFN-γR2 gene using allelic discrimination RT-PCR technique.** The oligonucleotide sequences flanking these SNPs were designed as primers for TaqMan allelic discrimination. The allele-specific probes were labeled with a fluorescent dye (VIC and FAM) and used in the allele typing of each DNA sample with real-time (RT) PCR reaction on the apparatus (Applied Biosystems, model 7500) using ready-made fluorescent-amide-labeled SNP primers and probes (purchased from Applied Biosystems) (Table1).

For 20 μL reaction volume, we used the following amounts of reagents: 10.0 μL of TaqMan Universal Master Mix II (2x) + 1.0 μL SNP Genotyping Assay Mix (20x) + 1.0 μL DNA template + 8.0 μL RNase free water + 20.0 μL total volume. This volume is multiplied by the number of replicates in the run. RT-PCR was performed in a thermal cycler (Applied Biosystems, 2720) with the following cycles: holding step at 95°C for 10 min, then 40 cycles of the denaturation step at 95°C for 15 s and the annealing/extension step at 60°C for 1 min.

**Statistical analysis.** Data were computed and statistically analyzed using SPSS software program (IBM Corp. Released 2012, Version 21.0. IBM SPSS Statistics for Windows; Armonk, NY, USA). We used chi-square and Fisher’s exact tests to compare quantitative variables. Hardy–Weinberg equilibrium was assessed in each group separately using χ² tests.

The allele carriage is defined as the number of individuals carrying at least one copy of a specific allele. Allelic frequencies are defined as the number of occurrences of the test allele divided by the total number of alleles in the group. The odds ratio (OR) at a 95% confidence interval (CI) of a specific allele carriage was calculated, compared with no carriage of the target allele, using Med Calc software (Med Calc statistical software version 16.4.3. Med Calc (software bvba, Ostend, Belgium)). The difference was considered significant if P ≤ 0.05. The Bonferroni-corrected P value (Pc) is an adjustment made to P values when several dependent or independent statistical tests are being performed simultaneously on a single dataset.

**Results**

The clinical and laboratory characteristics of the studied groups (SVC, CHC, and Negative control groups) are shown in Table 2. The distribution of allele frequencies of current (rs2430561 and rs2069707) SNPs of the IFN-γ gene was within the HWE. Heterozygosity and polymorphic information content (PIC) in all study groups was enough to conduct statistical analysis for Egyptians (Table 3). The SNP rs2069707 of the IFN-γ gene and rs 27860067 of the IFN-γR2 gene were not polymorphic in Egyptians, and all individuals were genotyped as AA and CC, respectively.

IFN-γ (+874 A/T) SNP was genotyped in Egyptian families with HCV using ARMS-PCR and SBT technique as shown in Table 3. The other SNPs were genotyped using TaqMan Allelic Discrimination protocol (Fig. 1). The distribution of the IFN-γ (+874 A/T) polymorphism genotype was 10.81% AA, 51.5%
Table 3  Distributions of IFN-γ (rs2430561 and rs2069707) SNPs among the study groups.

| SNP   | rs 2430561 (+874) (A/T) | rs 2069707 (−764) (G/C) |
|-------|-------------------------|-------------------------|
|       | Genotypes MAF (%)       | Genotypes MAF (%)       |
|       | AA AT TT (%)            | GG GC CC (%)            |
| SVC   | Genotypes MAF (%)       | Genotypes MAF (%)       |
| group | AA AT TT (%)            | GG GC CC (%)            |
|       | 51 31 18 34 30 31 7.455/0.0085 | 56.48 28.72 14.8 30 34 29 1.157/0.543 |
| CHC   | Genotypes MAF (%)       | Genotypes MAF (%)       |
| group | AA AT TT (%)            | GG GC CC (%)            |
|       | 11 51 38 63 36 52 3.786/0.051677 | 85.66 13.77 0.57 7 13 14 0.0012/0.9718 |
| Control group | Genotypes MAF (%) | Genotypes MAF (%) |
|       | AA AT TT (%)            | GG GC CC (%)            |
|       | 35 52 13 39 20 52 3.820/0.050626 | 86.26 13.04 0.70 7 12 13 0.5118/0.47435 |

CHC, positive hepatitis C virus; HET, heterozygosity; IFN-γ, interferon gamma; MAF, minor allele frequency; PIC, polymorphic information content; SNP, single-nucleotide polymorphism; SVC, spontaneous viral clearance.

Figure 1  +874 IFN-γ amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) gel. Part I: Ethidium bromide-stained 2% agarose gel for single-nucleotide polymorphism (SNP) IFN-γ (+874 A/T). PCR-ARMS product: (A) First well is a DNA marker of 100 bp. (B) Second and third wells are blank samples for forward 01 and forward 02 that has deionized water instead of the sample template. (C) Sample (1) has only two DNA bands for one well, one of them at 426 bp of human growth hormone (HGH) internal control and the other band at 261 bp of +874 A allele; however, the well of the T allele did not work, so these samples are negatives for the +874 T allele. (D) Sample (2) has one DNA band of each well at 426 bp of (HGH) internal control and only one band at 261 bp of +874 A allele, with the absence of T allele band, so these samples are negatives for the +874 T allele. (E) Samples (3, 7, 8) have two bands for each well, one of which is of 261 bp, indicating the presence of the +874 A allele or +874 T allele, so these samples are positives for A and T alleles. The second band is the internal control (HGH), which is of 426 bp. (F) Samples (4, 5, 6) have one DNA band of each well at 426 bp of (HGH) internal control and only one band at 261 bp of +874 T allele with the absence of A allele band, so these samples are negatives for the +874 A allele. Part II: IFN-γ (+874 A/T) SNP using sequence-based typing technique. Lane (a): Representative sequence chromatographs of IFN-γ (+874T) intron 1 of homozygote sample TT. Lane (b): Representative sequence chromatographs of IFN-γ (+874A) intron 1 of homozygote sample AA. Lane (c): Representative sequence chromatographs of IFN-γ (+874T/A) intron 1 of heterozygote sample TA. IFN-γ, interferon gamma.
AT, and 37.77% TT in HCV-infected patients, whereas in HCV-negative patients, the distribution was 34.8% AA, 51.9% AT, and 13.3% TT. In the SVC group, the distribution was 50.9% AA, 30.6% AT, and 18.5% TT (Table 3).

IFN-γ genotyping for IFN-γ (−764 G/C, rs2069707) SNP was performed for common alleles using allelic discrimination with a RT-PCR technique, as shown in Figure 2. The distribution of the IFN-γ (−764 G/C) polymorphism genotype was 56% GG, 15% CC, and 29% GC in SVC group, whereas in HCV-infected patients, the distribution was 86% GG, 0.6% CC, and 14% GC. In HCV-negative patients, the distribution was 86% GG, 0.7% CC, and 13% GC (Table 3).

Figure 2  Real-time polymerase chain reaction charts for different genotypes of (−764 G/C) single nucleotide polymorphism of the interferon gamma gene. VIC, ROX and FAM are immunochromistry dyes. (a) Homozygote (GG): , FAM; , ROX; , VIC. (b) Homozygote (CC): , FAM; , ROX; , VIC. (c) Heterozygote (GC): , FAM; , ROX; , VIC.
Comparing the allele carriage of at least one copy of minor allele of each SNP revealed that the carriage of allele T IFN-\(\gamma\) +874 T/A, rs2430561 was associated with increased risk in HCV patients compared to that of noninfected exposed persons (Or = 9.7905, 95% CI 7.3818–12.9853, \(P < 0.0001\)). The T allele was also associated with HCV-positive patients compared with individuals with SVC (Or = 2.6646, 95% CI = 1.8888–4.4688, \(P = 0.0002\)) (Table 4). There was no significant difference between the carriage of allele T in SVC and HCV-negative patients (Or = 0.6741, 95% CI = 0.3914–1.1611, \(P = 0.1551\), suggesting that the A allele may have a role in protection against HCV infection, as shown in Table 4.

Analysis of the frequency of IFN-\(\gamma\) –764 GC, rs 2069707 alleles revealed that the C allele was a protective allele, and a highly statistical significant difference (\(P < 0.0001\)) was found between the SVC and HCV-positive groups (Or = 2.7090, 95% CI = 1.7980–4.4083). However, on comparing the HCV-positive and HCV-negative groups, there was no statistical significant difference (\(P = 0.9598\)), as shown in Table 4.

**Discussion**

IFN-\(\gamma\) is a key regulatory cytokine that plays a pivotal role in the defense mechanisms against viral infection in addition to its fibrogenic activity.\(^{10,20}\)

Because pro-/anti-inflammatory cytokines play a key role in the development of liver injury, genomic scanning for SNPs in the genes of several important inflammatory mediators needs to be further investigated, which could help to identify patients at markedly increased risks of live virus disease progression and could guide the design of individualized treatment strategies for hepatitis C infection.\(^{10,12,21,22}\)

However, the pattern of association between the IFN-\(\gamma\) +874 T/A gene polymorphism and viral hepatitis is inconclusive.\(^{23}\) Based on this polymorphism, three genotypes are possible: T/T, T/A, and A/A.\(^{24}\) T-to-A polymorphic sequence at position +874 in the IFN-\(\gamma\) gene (+874 IFN-\(\gamma\) T) might be associated with disease susceptibilities.\(^{25}\) Our study was conducted to determine allele frequencies in the IFN-\(\gamma\) gene at position +874 among Egyptian patients and to evaluate the association of IFN-\(\gamma\), (rs2430561) gene polymorphisms with HCV infection outcomes in the Egyptian population.

Our results found that the T allele of IFN-\(\gamma\) +874 rs2430561 is significantly higher in CHCV patients than the SVC and control patients; therefore, they are associated with increasing risk of HCV infection. While the A allele had a higher frequency in HCV-negative and SVC groups, they were associated with a decreasing risk of HCV infection.

Our results support some studies’ results which found that the number of TT genotype individuals was significantly elevated when compared to TA genotype subjects.\(^{21,26,27}\) Bouzgarrou et al. conducted a study on Caucasian individuals and found a significantly higher rate of TT and TA genotypes in patients with cirrhosis and HCC, respectively.\(^{28}\)

A study conducted on patients from Southern Iran with genotypes 1, 2, and 3 demonstrated no association between IFN-\(\gamma\) +874 polymorphisms and HCV infection outcomes. However, clearance was associated only with haplotype (A allele at +874 loci and G allele at +2109 loci),\(^{29}\) whereas liver cirrhosis was reported to be associated with the T allele at position +874 of the IFN-\(\gamma\) gene in HCV-infected Taiwanese patients.\(^{30}\)

In contrast to our results, a study conducted on Caucasian patients who underwent liver transplantation for end-stage liver disease due to HCV infection revealed that the IFN-\(\gamma\) +874 polymorphism genotypes are not related to liver fibrosis progression in recurrent hepatitis C patients.\(^{20}\)

Another study on Asian and Caucasian populations discovered that the T allele is a protective gene in liver disease and is more powerful than the A allele, where the +874 AA genotype is associated with a 1.350-fold increased risk of hepatitis virus-related disease, especially in the Asian population; the IFN-\(\gamma\) +874 TT genotype increases the level of IFN-\(\gamma\) production; and the AA and TA genotypes result in a decrease in IFN-\(\gamma\) production.\(^{23}\) On the other hand, it was reported that the IFN-\(\gamma\) +874 AA genotype was associated with an increased risk of mild and/or moderate/severe chronic hepatitis and cirrhosis, but the +874 TA genotype was associated with reduced risk, although the IFN-\(\gamma\) +874 T/A alleles did not differ between any of the groups.\(^{31}\) When a comparison between populations from different ethnic backgrounds was made, it was found that the frequency of the IFN-\(\gamma\) genotypes A/A was associated with low expression in CHC patients and was significantly higher in African Americans than in Caucasian or Cuban Americans.\(^{30}\) In Irish individuals, there was no significant difference in the frequency of genotypes associated with polymorphisms of the IFN-\(\gamma\) gene between individuals with viral clearance or those with persistent HCV infection and Irish women.\(^{24}\)

IFN-\(\gamma\) +874 T/A polymorphism may affect the development of HCV infection through different mechanisms. First, the IFN-\(\gamma\) +874 T/A genotype TT, which produces a high level of IFN-\(\gamma\), aids the host’s antiviral defense system. In contrast, the AA and TA genotypes result in low IFN-\(\gamma\) production, potentially increasing the risk of hepatitis virus infection.\(^{9}\) Second, as described earlier, IFN-\(\gamma\) binds to a specific cell-surface receptor.

---

**Table 4** Association of minor allele of rs2430561 (T) and rs2069707 (C) of IFN-\(\gamma\) polymorphism among the study groups

|                  | rs 2430561 (+874 T) | rs 2069707 (–764 C) |
|------------------|---------------------|----------------------|
| SVC versus control | 0.6741 (0.3914–1.1611) | 0.155 (NA) |
| SVC versus CHC | 2.6646 (1.8888–4.4688) | 0.0002 (0.0006) |
| CHC versus control | 9.7905 (7.3818–12.9853) | 0.0001 (0.0003) |
|                  | 0.2709 (0.1798–0.4083) | 0.0001 (0.0001) |
|                  | 0.2709 (0.1884–0.4321) | 0.0001 (0.0001) |
|                  | 0.95980 (0.07565–1.4349) | 0.95980 (NA) |
Interferon gamma genetic polymorphism

M El-Bendary et al.

Our study included a substantial number of cases and controls pooled from different areas, which greatly increased the statistical power compared with other studies, which provides explanations for the inconsistencies observed in previous studies.

Acknowledgment

The authors thank the Medical Biochemistry Department and Medical Experimental Research Centre (MERC), Mansoura Faculty of Medicine, for their kind help and support in the completion of routine laboratory work.

References

1 Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011; 17: 107–15.
2 World Health Organization. Hepatitis C-Fact Sheet (No 164); 2014; http://www.who.int/mediacentre/factsheets/fs164_apr2014/en/
3 Khatab MA, Ferenci P, Hadzijannis SJ et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J. Hepatol. 2011; 54: 1250–62.
4 Wantuck J, Ahmed A, Nguyen M. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment. Pharmacol. Ther. 2014; 39: 137–47.
5 Metz P, Reuter A, Bender S, Battenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J. Hepatol. 2013; 59: 1331–41.
6 Urban T, Charlton MR, Goldstein DB. Introduction to the genetics and biology of interferon-28B. Hepatology. 2012; 56: 361–6.
7 Schena FP, Cerullo G, Torres DD et al. Role of interferon-γ gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur. J. Hum. Genet. 2006; 14: 488–96.
8 Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott P, Hutchinson I. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur. J. Immunogenet. 1999; 26: 1–3.
9 Pravica V, Perrey C, Stevens A, Lee J-H, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-γ gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ production. Hum. Immunol. 2000; 61: 863–6.
10 Huang Y, Yang H, Borg BB et al. A functional SNP of interferon-γ gene is important for interferon-α-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl. Acad. Sci. 2007; 104: 985–90.
11 Bream J, Ping A, Zhang X, Winkler C, Young H. A single nucleotide polymorphism in the proximal IFN-γ promoter alters control of IFN-γ production. Hum. Immunol. 2000; 61: 863–6.
12 Azam S, Manzoor S, Imran M et al. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection. Viral Immunol. 2015; 28: 222–8.
13 Bream JH, Carrington M, O’Ttole S et al. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics. 2000; 51: 50–8.
14 Fieschi C, Dupuis S, Picard C, Smith CE, Holland SM, Casanova J-L. High levels of interferon gamma in the plasma of children with complete interferon gamma receptor deficiency. Pediatrics. 2001; 107: e48.
17 Nalpas B, Lavialle-Meziani R, Plancoulaine S et al. Interferon γ receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection. *Gut*. 2010; 59: 1120–6.
18 Thomas VP. What’s wrong with Bonferroni adjustments. *BMJ*. 1998; 316: 1236–8.
19 Mullikin J, Hunt S, Cole C et al. An SNP map of human chromosome 22. *Nature*. 2000; 407: 516–20.
20 Falletti E, Fabris C, Toniutto P et al. Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. *J. Interferon Cytokine Res.* 2007; 27: 239–46.
21 Colakogullari M, Ulukaya E, Yilmaztepe Oral A et al. The involvement of IL-10, IL-6, IFN-γ, TNF-α and TGF-β gene polymorphisms among Turkish lung cancer patients. *Cell Biochem. Funct.* 2008; 26: 283–90.
22 Wang Z-E, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. *J. Exp. Med.* 1994; 179: 1367–71.
23 Sun Y, Lu Y, Li T et al. Interferon gamma+ 874T/A polymorphism increases the risk of hepatitis virus-related diseases: evidence from a meta-analysis. *PLoS One*. 2015; 10: e0121168.
24 Barrett S, Collins M, Kenny C, Ryan E, Keane C, Crowe J. Polymorphisms in tumour necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6, interferon-γ, and outcome of hepatitis C virus infection. *J. Med. Virol.* 2003; 71: 212–8.
25 Dai C-Y, Chuang W-L, Hsieh M-Y et al. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C. *Transl. Res.* 2006; 148: 128–33.
26 Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L. Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. *Int. J. Immunogenet.* 2008; 35: 197–205.
27 Forte GI, Scola L, Misiano G et al. Relevance of gamma interferon, tumor necrosis factor alpha, and interleukin-10 gene polymorphisms to susceptibility to Mediterranean spotted fever. *Clin. Vaccine Immunol.* 2009; 16: 811–5.
28 Bouzgarrou N, Hassen E, Farhat K et al. Combined analysis of interferon-γ and interleukin-10 gene polymorphisms and chronic hepatitis C severity. *Hum. Immunol.* 2009; 70: 230–6.
29 Sarvari J, Moattari A, Pirbonyeh N, Moini M, Hosseini SY. The Impact of IFN-γ gene polymorphisms on spontaneous clearance of HCV infection in Fars Province, Southern of Iran. *J. Clin. Lab. Anal.* 2015; 30: 301–7.
30 Delaney NL, Esquenazi V, Lucas DP, Zachary AA, Leffell MS. TNF-α, TGF-β, IL-10, IL-6, and INF-γ alleles among African Americans and Cuban Americans. Report of the ASHI minority workshops: part IV. *Hum. Immunol.* 2004; 65: 1413–9.
31 Gao J, Liu D-W, Zhang S-Y et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. *World J. Gastroenterol.* 2009; 15: 5610–9.
32 Sweetser MT, Hoey T, Sun Y-L, Weaver WM, Price GA, Wilson CB. The roles of nuclear factor of activated T cells and ying-yang 1 in activation-induced expression of the interferon-γ promoter in T cells. *J. Biol. Chem.* 1998; 273: 34775–83.
33 Sica A, Tan T-H, Rice N, Kretzschmar M, Ghosh P, Young HA. The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element. *Proc. Natl. Acad. Sci.* 1992; 89: 1740–4.
34 Sica A, Dorman L, Viggiano V et al. Interaction of NF-κB and NFAT with the interferon-γ promoter. *J. Biol. Chem.* 1997; 272: 30412–20.
35 Wang D, Zhong X, Huang D et al. Functional polymorphisms of interferon-gamma affect pneumonia-induced sepsis. *PLoS One.* 2014; 9: e87049.
36 Al-Muhsein S, Casanova J-L. The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. *J. Allergy Clin. Immunol.* 2008; 122: 1043–51.